This article is more than 5 years old. Information may no longer be current.

Alnylam study shows RNAi therapy effective in rat model

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CAMBRIDGE, Mass. — An RNA-interference drug was effective in silencing the expression of vascular endothelial growth factor a rat model, according to Alnylam Pharmaceuticals. The company issued a press release based on data presented on its drug at the Macula Society meeting.

In preclinical studies performed in a rat model of age-related macular degeneration with laser-induced choroidal neovascularization, the RNAi therapeutic reduced pathological vascular leakage compared with a placebo control, the company said in the press release.

Alnylam is working with Merck to develop RNAi therapeutics for the treatment of ocular microvascular diseases.